{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:28:23Z","timestamp":1740144503836,"version":"3.37.3"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Projekt DEAL"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n              <jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rare diseases (RDs) in rheumatology as a group have a high prevalence, but randomized controlled trials are hampered by their heterogeneity and low individual prevalence. To survey the current evidence of pharmacotherapies for rare rheumatic diseases, we conducted a systematic review and meta-analysis. Randomized controlled trials (RCTs) of RDs in rheumatology for different pharmaco-interventions were included into this meta-analysis if there were two or more trials investigating the same RD and using the same assessment tools or outcome parameters. The Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and PUBMED were searched up to April 2nd 2020. The overall objective of this study was to identify RCTs of RDs in rheumatology, evaluate the overall quality of these studies, outline the evidence of pharmacotherapy, and summarize recommended therapeutic regimens.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We screened 187 publications, and 50 RCTs met our inclusion criteria. In total, we analyzed data of 13 different RDs. We identified several sources of potential bias, such as a lack of description of blinding methods and allocation concealment, as well as small size of the study population. Meta-analysis was possible for 26 studies covering six RDs: Hunter disease, Beh\u00e7et\u2019s disease, giant cell arteritis, ANCA-associated vasculitis, reactive arthritis, and systemic sclerosis. The pharmacotherapies tested in these studies consisted of immunosuppressants, such as corticosteroids, methotrexate and azathioprine, or biologicals. We found solid evidence for idursulfase as a treatment for Hunter syndrome. In Beh\u00e7et\u2019s disease, apremilast and IF-\u03b1 showed promising results with regard to total and partial remission, and Tocilizumab with regard to relapse-free remission in giant cell arteritis. Rituximab, cyclophosphamide, and azathioprine were equally effective in ANCA-associated vasculitis, while mepolizumab improved the efficacy of glucocorticoids. The combination of rifampicin and azithromycin showed promising results in reactive arthritis, while there was no convincing evidence for the efficacy of pharmacotherapy in systemic sclerosis.<\/jats:p>\n              <\/jats:sec>\n              <jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>For some diseases such as systemic sclerosis, ANCA-associated vasculitis, or Behcet's disease, higher quality trials were available. These RCTs showed satisfactory efficacies for immunosuppressants or biological drugs, except for systemic sclerosis. More high quality RCTs are urgently warranted for a wide spectrum of RDs in rheumatology.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01576-5","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T13:03:13Z","timestamp":1604149393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Therapeutic options for patients with rare rheumatic diseases: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Tim T. A.","family":"Bender","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Leyens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Sellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitrij","family":"Kravchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9275-9035","authenticated-orcid":false,"given":"Martin","family":"M\u00fccke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias F.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"1576_CR1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/annrheumdis-2016-eular.4056","volume":"75","author":"J Leyens","year":"2016","unstructured":"Leyens J, Stieber C, Bender TTA, M\u00fccke M, Seidel MF. FRI0495 the combined prevalence of rare diseases in rheumatology demonstrates a sum more than double to that of ankylosing spondylitis. Ann Rheum Dis. 2016;75:618\u2013618.","journal-title":"Ann Rheum Dis"},{"key":"1576_CR2","unstructured":"Anonymous. Rare diseases. In: Gesundheitswesen - Eur. Comm. (2016). \n                  https:\/\/ec.europa.eu\/health\/non_communicable_diseases\/rare_diseases_de\n                  \n                . Accessed 28 Feb 2019"},{"key":"1576_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0627-0","author":"S Exarchou","year":"2015","unstructured":"Exarchou S, Lindstr\u00f6m U, Askling J, Eriksson JK, Forsblad-d\u2019Elia H, Neovius M, Turesson C, Kristensen LE, Jacobsson LT. The prevalence of clinically diagnosed ankylosing spondylitis and its clinical manifestations: a nationwide register study. Arthritis Res Ther. 2015. \n                  https:\/\/doi.org\/10.1186\/s13075-015-0627-0\n                  \n                .","journal-title":"Arthritis Res Ther"},{"key":"1576_CR4","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1136\/annrheumdis-2013-204991","volume":"74","author":"R Levy","year":"2015","unstructured":"Levy R, G\u00e9rard L, Kuemmerle-Deschner J, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis. 2015;74:2043\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1576_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/01.bor.0000126150.04251.f9","volume":"16","author":"H Zeidler","year":"2004","unstructured":"Zeidler H, Kuipers J, K\u00f6hler L. Chlamydia-induced arthritis. Curr Opin Rheumatol. 2004;16:380\u201392.","journal-title":"Curr Opin Rheumatol"},{"key":"1576_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.4103\/0019-5154.113930","volume":"58","author":"V Viswanath","year":"2013","unstructured":"Viswanath V, Phiske MM, Gopalani VV. Systemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations. Indian J Dermatol. 2013;58:255\u201368.","journal-title":"Indian J Dermatol"},{"key":"1576_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1613849","volume":"377","author":"JH Stone","year":"2017","unstructured":"Stone JH, Tuckwell K, Dimonaco S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377:317\u201328.","journal-title":"N Engl J Med"},{"key":"1576_CR8","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1056\/NEJMoa1408684","volume":"372","author":"G Hatemi","year":"2015","unstructured":"Hatemi G, Melikoglu M, Tunc R, et al. Apremilast for Beh\u00e7et\u2019s syndrome\u2013a phase 2, placebo-controlled study. N Engl J Med. 2015;372:1510\u20138.","journal-title":"N Engl J Med"},{"key":"1576_CR9","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Green S, Cochrane Collaboration (eds) (2008) Cochrane handbook for systematic reviews of interventions. Wiley-Blackwell, Chichester, England; Hoboken, NJ","DOI":"10.1002\/9780470712184"},{"key":"1576_CR10","unstructured":"Deeks J, Higgins JPT. Statistical algorithms in Review Manager 5 (2010)."},{"key":"1576_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/humu.1380020603","volume":"2","author":"JJ Hopwood","year":"1993","unstructured":"Hopwood JJ, Bunge S, Morris CP, Wilson PJ, Steglich C, Beck M, Schwinger E, Gal A. Molecular basis of mucopolysaccharidosis type II: Mutations in the iduronate-2-sulphatase gene. Hum Mutat. 1993;2:435\u201342.","journal-title":"Hum Mutat"},{"key":"1576_CR12","first-page":"465","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med Off J Am Coll Med Genet. 2006;8:465\u201373.","journal-title":"Genet Med Off J Am Coll Med Genet"},{"key":"1576_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-8-42","volume":"8","author":"YB Sohn","year":"2013","unstructured":"Sohn YB, Cho SY, Park SW, Kim SJ, Ko A-R, Kwon E-K, Han SJ, Jin D-K. Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter syndrome). Orphanet J Rare Dis. 2013;8:42.","journal-title":"Orphanet J Rare Dis"},{"key":"1576_CR14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1590\/abd1806-4841.20177359","volume":"92","author":"MAR Scherrer","year":"2017","unstructured":"Scherrer MAR, Rocha VB, Garcia LC. Beh\u00e7et\u2019s disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92:452\u201364.","journal-title":"An Bras Dermatol"},{"key":"1576_CR15","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1001\/archderm.138.4.467","volume":"138","author":"E Alpsoy","year":"2002","unstructured":"Alpsoy E, Durusoy C, Yilmaz E, Ozgurel Y, Ermis O, Yazar S, Basaran E. Interferon alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467\u201371.","journal-title":"Arch Dermatol"},{"key":"1576_CR16","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/rheumatology\/kei165","volume":"45","author":"C Mat","year":"2006","unstructured":"Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H. A double-blind trial of depot corticosteroids in Beh\u00e7et\u2019s syndrome. Rheumatol Oxf Engl. 2006;45:348\u201352.","journal-title":"Rheumatol Oxf Engl"},{"key":"1576_CR17","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","volume":"44","author":"S Yurdakul","year":"2001","unstructured":"Yurdakul S, Mat C, T\u00fcz\u00fcn Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak M, Yazici H. A double-blind trial of colchicine in Beh\u00e7et\u2019s syndrome. Arthritis Rheum. 2001;44:2686\u201392.","journal-title":"Arthritis Rheum"},{"key":"1576_CR18","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","volume":"381","author":"G Hatemi","year":"2019","unstructured":"Hatemi G, Mahr A, Ishigatsubo Y, et al. Trial of apremilast for oral ulcers in Beh\u00e7et\u2019s syndrome. N Engl J Med. 2019;381:1918\u201328.","journal-title":"N Engl J Med"},{"key":"1576_CR19","first-page":"23","volume":"5","author":"P Patil","year":"2013","unstructured":"Patil P, Karia N, Jain S, Dasgupta B. Giant cell arteritis: a review. Eye Brain. 2013;5:23\u201333.","journal-title":"Eye Brain"},{"key":"1576_CR20","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7326\/0003-4819-146-9-200705010-00004","volume":"146","author":"GS Hoffman","year":"2007","unstructured":"Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, Salvarani C, Xu W, Visvanathan S, Rahman MU. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med. 2007;146:621\u201330.","journal-title":"Ann Intern Med"},{"key":"1576_CR21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/art.10262","volume":"46","author":"GS Hoffman","year":"2002","unstructured":"Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002;46:1309\u201318.","journal-title":"Arthritis Rheum"},{"key":"1576_CR22","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1136\/annrheumdis-2013-203586","volume":"73","author":"R Seror","year":"2014","unstructured":"Seror R, Baron G, Hachulla E, et al. Adalimumab for steroid sparing in patients with giant-cell arteritis: results of a multicentre randomised controlled trial. Ann Rheum Dis. 2014;73:2074\u201381.","journal-title":"Ann Rheum Dis"},{"key":"1576_CR23","doi-asserted-by":"publisher","first-page":"106","DOI":"10.7326\/0003-4819-134-2-200101160-00010","volume":"134","author":"JA Jover","year":"2001","unstructured":"Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106\u201314.","journal-title":"Ann Intern Med"},{"key":"1576_CR24","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1002\/art.22163","volume":"54","author":"M Mazlumzadeh","year":"2006","unstructured":"Mazlumzadeh M, Hunder GG, Easley KA, Calamia KT, Matteson EL, Griffing WL, Younge BR, Weyand CM, Goronzy JJ. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006;54:3310\u20138.","journal-title":"Arthritis Rheum"},{"key":"1576_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-017-0364-x","author":"M Calatroni","year":"2017","unstructured":"Calatroni M, Oliva E, Gianfreda D, et al. ANCA-associated vasculitis in childhood: recent advances. Ital J Pediatr. 2017. \n                  https:\/\/doi.org\/10.1186\/s13052-017-0364-x\n                  \n                .","journal-title":"Ital J Pediatr"},{"key":"1576_CR26","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"ME Wechsler","year":"2017","unstructured":"Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376:1921\u201332.","journal-title":"N Engl J Med"},{"key":"1576_CR27","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211\u201320.","journal-title":"N Engl J Med"},{"key":"1576_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332.","journal-title":"N Engl J Med"},{"key":"1576_CR29","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1056\/NEJMoa1213277","volume":"369","author":"U Specks","year":"2013","unstructured":"Specks U, Merkel PA, Seo P, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. N Engl J Med. 2013;369:417\u201327.","journal-title":"N Engl J Med"},{"key":"1576_CR30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3329\/jhpn.v31i3.16515","volume":"31","author":"AN Ajene","year":"2013","unstructured":"Ajene AN, Walker CLF, Black RE. Enteric pathogens and reactive arthritis: a systematic review of campylobacter, salmonella and shigella-associated reactive arthritis. J Health Popul Nutr. 2013;31:299\u2013307.","journal-title":"J Health Popul Nutr"},{"key":"1576_CR31","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/art.1780391211","volume":"39","author":"DO Clegg","year":"1996","unstructured":"Clegg DO, Reda DJ, Weisman MH, et al. Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter\u2019s syndrome). A Department of Veterans Affairs Cooperative Study. Arthritis Rheum. 1996;39:2021\u20137.","journal-title":"Arthritis Rheum"},{"key":"1576_CR32","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1136\/ard.2005.045484","volume":"65","author":"N Putschky","year":"2006","unstructured":"Putschky N, Pott H, Kuipers J, Zeidler H, Hammer M, Wollenhaupt J. Comparing 10-day and 4-month doxycycline courses for treatment of Chlamydia trachomatis-reactive arthritis: a prospective, double-blind trial. Ann Rheum Dis. 2006;65:1521\u20134.","journal-title":"Ann Rheum Dis"},{"key":"1576_CR33","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/art.27394","volume":"62","author":"J Carter","year":"2010","unstructured":"Carter J, Espinoza L, Inman R, et al. Combination antibiotics as a treatment for chronic Chlamydia-induced reactive arthritis: a double-blind, placebo-controlled, prospective trial. Arthritis Rheum. 2010;62:1298\u2013307.","journal-title":"Arthritis Rheum"},{"key":"1576_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00272","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik D, Brown M, Postlethwaite BC, Postlethwaite AE. Pathogenesis of systemic sclerosis. Front Immunol. 2015. \n                  https:\/\/doi.org\/10.3389\/fimmu.2015.00272\n                  \n                .","journal-title":"Front Immunol"},{"key":"1576_CR35","first-page":"503","volume":"19","author":"R Scorza","year":"2001","unstructured":"Scorza R, Caronni M, Mascagni B, Berruti V, Bazzi S, Micallef E, Arpaia G, Sardina M, Origgi L, Vanoli M. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud\u2019s phenomenon: a randomized, controlled study. Clin Exp Rheumatol. 2001;19:503\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1576_CR36","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kel038","volume":"45","author":"G Milio","year":"2006","unstructured":"Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S. Iloprost treatment in patients with Raynaud\u2019s phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol. Rheumatol Oxf Engl. 2006;45:999\u20131004.","journal-title":"Rheumatol Oxf Engl"},{"key":"1576_CR37","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1002\/art.27636","volume":"62","author":"JR Seibold","year":"2010","unstructured":"Seibold JR, Denton CP, Furst DE, et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum. 2010;62:2101\u20138.","journal-title":"Arthritis Rheum"},{"key":"1576_CR38","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.3899\/jrheum.090270","volume":"36","author":"E Schiopu","year":"2009","unstructured":"Schiopu E, Hsu V, Impens A, Rothman J, McCloskey D, Wilson J, Phillips K, Seibold J. Randomized placebo-controlled crossover trial of tadalafil in Raynaud\u2019s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264\u20138.","journal-title":"J Rheumatol"},{"issue":"Suppl 106","key":"1576_CR39","first-page":"151","volume":"35","author":"FV Andrigueti","year":"2017","unstructured":"Andrigueti FV, Ebbing PCC, Arismendi MI, Kayser C. Evaluation of the effect of sildenafil on the microvascular blood flow in patients with systemic sclerosis: a randomised, double-blind, placebo-controlled study. Clin Exp Rheumatol. 2017;35(Suppl 106):151\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"1576_CR40","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655\u201366.","journal-title":"N Engl J Med"},{"key":"1576_CR41","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/art.24380","volume":"60","author":"D Khanna","year":"2009","unstructured":"Khanna D, Clements PJ, Furst DE, et al. Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2009;60:1102\u201311.","journal-title":"Arthritis Rheum"},{"key":"1576_CR42","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"key":"1576_CR43","unstructured":"Efficacy and safety of rilonacept (interleukin-1 trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies - Hoffman - 2008 - Arthritis & Rheumatology - Wiley Online Library. http:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/art.23687\/full. Accessed 20 Oct 2016"},{"key":"1576_CR44","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","volume":"360","author":"HJ Lachmann","year":"2009","unstructured":"Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, Leslie KS, Hachulla E, Quartier P, Gitton X, Widmer A, Patel N, Hawkins PN. Use of Canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416\u201325.","journal-title":"N Engl J Med"},{"key":"1576_CR45","first-page":"123","volume":"9","author":"T-A Tran","year":"2017","unstructured":"Tran T-A. Muckle&ndash; Wells syndrome: clinical perspectives. Open Access Rheumatol Res Rev. 2017;9:123\u20139.","journal-title":"Open Access Rheumatol Res Rev"},{"key":"1576_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1576_CR47","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.3899\/jrheum.111549","volume":"39","author":"D Nordstr\u00f6m","year":"2012","unstructured":"Nordstr\u00f6m D, Knight A, Luukkainen R, et al. Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still\u2019s disease. An open, randomized, multicenter study. J Rheumatol. 2012;39:2008\u201311.","journal-title":"J Rheumatol"},{"key":"1576_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s004150050005","volume":"247","author":"MC Walter","year":"2000","unstructured":"Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, Muller-Felber W, Pongratz D. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22\u20138.","journal-title":"J Neurol"},{"key":"1576_CR49","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1186\/s13063-017-2287-7","volume":"18","author":"A Rath","year":"2017","unstructured":"Rath A, Salamon V, Peixoto S, et al. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome? Trials. 2017;18:556.","journal-title":"Trials"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01576-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01576-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T17:04:02Z","timestamp":1604423042000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01576-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1576"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01576-5","relation":{},"ISSN":["1750-1172"],"issn-type":[{"type":"electronic","value":"1750-1172"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"19 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"308"}}